Advised Legend Biotech on its $487.3 million initial public offering. Legend Biotech, whose securities now trade on the Nasdaq Global Market under the symbol “LEGN”, is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications